ACBT (4148) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 全宇生技-KY

ACBT (4148) reported revenue of NT$323 million for Oct 2026, -2.0% year on year and -12.1% from the previous month. Revenue for Jan–Oct 2026 was NT$2.93 billion (+19.7% year on year).

In Oct 2026, it ranked No. 31 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$255.6 million24/10Nov 2024 NT$219.9 millionDec 2024 NT$241.9 millionJan 2025 NT$129.3 millionFeb 2025 NT$157.1 million25/02Mar 2025 NT$262.6 millionApr 2025 NT$233.5 millionMay 2025 NT$226.8 millionJun 2025 NT$263.6 million25/06Jul 2025 NT$253.3 millionAug 2025 NT$242.4 millionSep 2025 NT$348.9 millionOct 2025 NT$329.7 million25/10Nov 2025 NT$233.6 millionDec 2025 NT$272.2 millionJan 2026 NT$145.1 millionFeb 2026 NT$174.1 million26/02Mar 2026 NT$213.7 millionApr 2026 NT$362 millionMay 2026 NT$276.2 millionJun 2026 NT$346.7 million26/06Jul 2026 NT$353 millionAug 2026 NT$368.4 millionSep 2026 NT$367.4 millionOct 2026 NT$323 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$323 million-2.0%-12.1%
Sep 2026NT$367.4 million+5.3%-0.3%
Aug 2026NT$368.4 million+51.9%+4.4%
Jul 2026NT$353 million+39.3%+1.8%
Jun 2026NT$346.7 million+31.5%+25.5%
May 2026NT$276.2 million+21.8%-23.7%
Apr 2026NT$362 million+55.0%+69.4%
Mar 2026NT$213.7 million-18.6%+22.8%
Feb 2026NT$174.1 million+10.8%+20.0%
Jan 2026NT$145.1 million+12.2%-46.7%
Dec 2025NT$272.2 million+12.5%+16.5%
Nov 2025NT$233.6 million+6.3%-29.1%
Oct 2025NT$329.7 million+29.0%-5.5%
Sep 2025NT$348.9 million+34.0%+43.9%
Aug 2025NT$242.4 million-14.3%-4.3%
Jul 2025NT$253.3 million+16.7%-3.9%
Jun 2025NT$263.6 million+66.8%+16.2%
May 2025NT$226.8 million+21.4%-2.9%
Apr 2025NT$233.5 million+76.2%-11.1%
Mar 2025NT$262.6 million+46.7%+67.2%
Feb 2025NT$157.1 million-13.7%+21.5%
Jan 2025NT$129.3 million-19.9%-46.6%
Dec 2024NT$241.9 million+60.6%+10.0%
Nov 2024NT$219.9 million-3.3%-14.0%
Oct 2024NT$255.6 million+34.7%-1.8%

Jan–Oct 2026 cumulative: NT$2.93 billion (+19.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: ACBT vs PEC / ACBT vs Lotus Pharm / ACBT vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16